Iovance Biotherapeutics, Inc.
IOVA
$2.45
-$0.08-3.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 241.53M | 212.68M | 164.07M | 90.86M | 32.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 241.53M | 212.68M | 164.07M | 90.86M | 32.77M |
| Cost of Revenue | 191.77M | 166.48M | 124.00M | 82.82M | 47.33M |
| Gross Profit | 49.75M | 46.20M | 40.08M | 8.04M | -14.56M |
| SG&A Expenses | 163.68M | 165.55M | 153.02M | 140.42M | 127.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 652.16M | 611.46M | 559.35M | 520.82M | 492.03M |
| Operating Income | -410.64M | -398.78M | -395.28M | -429.96M | -459.25M |
| Income Before Tax | -389.73M | -378.62M | -375.01M | -416.14M | -446.08M |
| Income Tax Expenses | 188.00K | -3.26M | -2.83M | -6.15M | -5.87M |
| Earnings from Continuing Operations | -389.92 | -375.36 | -372.18 | -410.00 | -440.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -389.92M | -375.36M | -372.18M | -410.00M | -440.22M |
| EBIT | -410.64M | -398.78M | -395.28M | -429.96M | -459.25M |
| EBITDA | -376.29M | -365.02M | -362.11M | -398.45M | -429.38M |
| EPS Basic | -1.23 | -1.23 | -1.30 | -1.50 | -1.68 |
| Normalized Basic EPS | -0.78 | -0.79 | -0.83 | -0.96 | -1.08 |
| EPS Diluted | -1.23 | -1.23 | -1.30 | -1.50 | -1.68 |
| Normalized Diluted EPS | -0.78 | -0.79 | -0.83 | -0.96 | -1.08 |
| Average Basic Shares Outstanding | 1.27B | 1.22B | 1.16B | 1.11B | 1.05B |
| Average Diluted Shares Outstanding | 1.27B | 1.22B | 1.16B | 1.11B | 1.05B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |